-
Stocks rise, yields ease as oil slips on Trump hint at short bombing campaign
-
Hamilton hopes to boost title bid with record Italian triumph
-
Brussels Diamond League finals Day 1 - five events to watch
-
Iran, US trade threats after fresh strikes
-
Thailand's 'Jurassic Park' shines light on dinosaur evolution
-
US not 'stealing Venezuelan oil,' energy secretary insists
-
'Role model' Stokes set to open for Adelaide Strikers
-
Farming experts tout 'conscious' food systems to fix agriculture woes
-
Palau urges 'unified' Pacific response to China missile test
-
George Lucas unveils art galaxy at his new LA museum
-
Grinding away: in remote Appalachia, old mills fuel US clean food dreams
-
Veteran Wallaby Slipper targets fifth World Cup after Brumbies deal
-
Sabalenka races into US Open third round
-
Sabalenka storms into US Open third round as Pegula, Medvedev advance
-
Chinese lucky loser stuns Jodar at US Open
-
Zverev looks to improve after first-round scare
-
US Open under the influence: content creators spark debate
-
Raiders to start Cousins over top NFL Draft pick Mendoza
-
NBA hammers Clippers over Leonard salary cap violations
-
Palantir chief says France's digital sovereignty push 'backfiring'
-
NBA strips five first-round draft picks from Clippers for Leonard salary cap violations
-
US energy firms dominate Venezuela deals worth billions
-
Kane brace helps Bayern win German Cup opener
-
Iran, US trade threats after escalation in fighting
-
Migrant plight, local anger divide Ceuta one month after influx
-
US jury deadlocks again in Lindsay Clancy's child murder trial
-
Outrage as Maltese tycoon acquitted of reporter's murder
-
Lake America? No way, Canadians say
-
Rare train of Pacific cyclones fueled by historic El Nino
-
Spain report flags Moroccan police failings in Ceuta migrant rush
-
Macron, King Charles hail UK-France ties after viewing Bayeux Tapestry
-
Tech bosses press G20 to build data centers, but split on risk
-
Fury hits out at 'coward' Joshua as 'Battle of Britain' talks go on
-
Dolly Parton to get new Hollywood star after vandalism
-
Maltese tycoon acquitted of masterminding reporter's murder
-
Trump 'happy' Prince Harry and Meghan have left US
-
George Clooney: a Hollywood icon and campaigner
-
Michelson shocks Nakashima in US Open clash of rising Americans
-
Europe, US closer than they look on tech rules, says EU tech chief
-
Another body recovered after ferry capsizes off northern Cyprus: official
-
Clooney honoured as Hollywood-light Venice Film Festival kicks off
-
Cupertino Chamber President Claudio Bono Invited to White House with GiveaRoof 3-Year Plan to End Homelessness
-
Third-ranked Pegula, Medvedev power into US Open third round
-
Trump floats renaming Strait of Hormuz as 'Trump Strait'
-
Davis-Woodhall a doubt for Ultimate Championship after car crash
-
Man City, Chelsea fuel record-breaking Premier League transfer window
-
Third-ranked Pegula powers into US Open third round
-
Balogun rejected Everton move over transfer 'treatment'
-
Uber says laying off 'about 10%' of workforce worldwide
-
Northampton seek 'happy medium' in bid to keep England star Pollock
Exousia Pro Issues Update on Name Change
ORLANDO, FLORIDA / ACCESS Newswire / April 3, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is pleased to announce that the Company has received comments from FINRA regarding the name change.
FINRA has requested specific Board minutes and the stamped Articles of Amendment from the State of Florida showing the name change from Marijuana, Inc. to Exousia Pro, Inc.
We submitted the Articles of Amendment to the filer yesterday, and they will be forwarded to the State this morning. To facilitate the Name change, the name of our subsidiary had to be changed from Exousia Pro, Inc. to Exousia AI, Inc., to release the name for the parent company.
"This is a positive indicator that the process is moving along, as evidenced by hearing from FINRA within the first 30 days of the filing," said Matthew Dwyer, President of Exousia Pro, Inc.
About us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
[email protected]
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
P.A.Mendoza--AT